Literature DB >> 34429328

Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity.

Sharon Grisaru-Tal1, Shai Dulberg2, Lir Beck3, Chunyan Zhang4, Michal Itan1, Soroor Hediyeh-Zadeh5,6, Julie Caldwell7, Perri Rozenberg1, Avishay Dolitzky1, Shmuel Avlas1, Inbal Hazut1, Yaara Gordon1, Ophir Shani2, Shlomo Tsuriel8, Motti Gerlic1, Neta Erez2, Nicolas Jacquelot5,9, Gabrielle T Belz5,6,10, Marc E Rothenberg7, Melissa J Davis5,6, Hua Yu4, Tamar Geiger3, Asaf Madi2, Ariel Munitz11.   

Abstract

The recognition of the immune system as a key component of the tumor microenvironment (TME) led to promising therapeutics. Because such therapies benefit only subsets of patients, understanding the activities of immune cells in the TME is required. Eosinophils are an integral part of the TME especially in mucosal tumors. Nonetheless, their role in the TME and the environmental cues that direct their activities are largely unknown. We report that breast cancer lung metastases are characterized by resident and recruited eosinophils. Eosinophil recruitment to the metastatic sites in the lung was regulated by G protein-coupled receptor signaling but independent of CCR3. Functionally, eosinophils promoted lymphocyte-mediated antitumor immunity. Transcriptome and proteomic analyses identified the TME rather than intrinsic differences between eosinophil subsets as a key instructing factor directing antitumorigenic eosinophil activities. Specifically, TNFα/IFNγ-activated eosinophils facilitated CD4+ and CD8+ T-cell infiltration and promoted antitumor immunity. Collectively, we identify a mechanism by which the TME trains eosinophils to adopt antitumorigenic properties, which may lead to the development of eosinophil-targeted therapeutics. SIGNIFICANCE: These findings demonstrate antitumor activities of eosinophils in the metastatic tumor microenvironment, suggesting that harnessing eosinophil activity may be a viable clinical strategy in patients with cancer. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34429328     DOI: 10.1158/0008-5472.CAN-21-0839

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.

Authors:  Sharon Grisaru-Tal; Marc E Rothenberg; Ariel Munitz
Journal:  Nat Immunol       Date:  2022-08-24       Impact factor: 31.250

2.  CCR3 blockage elicits polyploidization associated with the signatures of epithelial-mesenchymal transition in carcinoma cell lines.

Authors:  Yuichiro Kaibori; Daisuke Nagakubo
Journal:  Cancer Gene Ther       Date:  2022-09-19       Impact factor: 5.854

3.  Eosinophils Decrease Pulmonary Metastatic Mammary Tumor Growth.

Authors:  Rachel A Cederberg; Sarah Elizabeth Franks; Brennan J Wadsworth; Alvina So; Lisa R Decotret; Michael G Hall; Rocky Shi; Michael R Hughes; Kelly M McNagny; Kevin L Bennewith
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 4.  Eosinophils and melanoma: Implications for immunotherapy.

Authors:  India Robinson; Gabriella Santa Lucia; Andraia Li; Nathaniel Oberholtzer; John Plante; Kristen M Quinn; Daniel Reuben; Shikhar Mehrotra; Manuel Valdebran
Journal:  Pigment Cell Melanoma Res       Date:  2022-01-18       Impact factor: 4.159

5.  Molecular Signatures of Response to Mecasermin in Children With Rett Syndrome.

Authors:  Stephen Shovlin; Chloe Delepine; Lindsay Swanson; Snow Bach; Mustafa Sahin; Mriganka Sur; Walter E Kaufmann; Daniela Tropea
Journal:  Front Neurosci       Date:  2022-05-31       Impact factor: 5.152

6.  Transcriptional Profiling of Mouse Eosinophils Identifies Distinct Gene Signatures Following Cellular Activation.

Authors:  Avishay Dolitzky; Guy Shapira; Sharon Grisaru-Tal; Inbal Hazut; Shmulik Avlas; Yaara Gordon; Micahl Itan; Noam Shomron; Ariel Munitz
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

7.  Development and Validation of a 7-Gene Inflammatory Signature Forecasts Prognosis and Diverse Immune Landscape in Lung Adenocarcinoma.

Authors:  Aitao Nai; Feng Ma; Zirui He; Shuwen Zeng; Shoaib Bashir; Jian Song; Meng Xu
Journal:  Front Mol Biosci       Date:  2022-03-15

8.  The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.

Authors:  Yu-Wei Chen; Matthew D Tucker; Landon C Brown; Hesham A Yasin; Kristin K Ancell; Andrew J Armstrong; Kathryn E Beckermann; Nancy B Davis; Michael R Harrison; Elizabeth G Kaiser; Renee K McAlister; Kerry R Schaffer; Deborah E Wallace; Daniel J George; W Kimryn Rathmell; Brian I Rini; Tian Zhang
Journal:  Cancers (Basel)       Date:  2022-08-07       Impact factor: 6.575

Review 9.  The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma.

Authors:  Shuyue Zheng; Beilei Liu; Xinyuan Guan
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

10.  A robust CD8+ T cell-related classifier for predicting the prognosis and efficacy of immunotherapy in stage III lung adenocarcinoma.

Authors:  Jinteng Feng; Longwen Xu; Shirong Zhang; Luying Geng; Tian Zhang; Yang Yu; Rui Yuan; Yusheng He; Zhuhui Nan; Min Lin; Hui Guo
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.